Has Kabir Mody received payments from drug or device companies?

Yes. Drug and device makers reported $51,563 in general payments to Kabir Mody across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kabir Mody did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kabir Mody come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kabir Mody

Hematology & Oncology · Jacksonville, FLNPI 1902096860

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $42,509 of the $51,563 with a category attached, or 82.4%. 11 manufacturers reported payments, led by AstraZeneca at 52.3% of the total. Reporting peaked in 2020 at $26,331 and has fallen 99.8% since, to $46 in 2024.

$51,563in general payments, 2019–2025

Across 42 payments — averaging $1227.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$27K
Ipsen Biopharmaceuticals, Inc$7K
Exelixis Inc.$7K
Genentech USA, Inc.$6K
Biocompatibles, Inc.$2K
Boston Scientific$2K
plus $489 from 5 others

$2,394,663in research payments, 2019–2025

Across 497 payments — averaging $4818.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$1.4M
EMD Serono, Inc.$497K
Incyte Corporation$235K
Puma Biotechnology, Inc.$106K
Agios Pharmaceuticals, Inc.$45K
Ipsen Bioscience Inc.$26K
plus $36K from 3 others

What the payments were for

Consulting fees$42,50982%
Speaking & faculty fees$5,28010%
Travel & lodging$1,6263%
Food & beverage$2,1484%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	8	$26,949
Ipsen Biopharmaceuticals, Inc	10	$7,324
Exelixis Inc.	9	$6,681
Genentech USA, Inc.	5	$5,523
Biocompatibles, Inc.	2	$2,480
Boston Scientific	2	$2,117
Astrazeneca AB	2	$188
Novocure Inc.	1	$138
Amgen	1	$91
Merck	1	$46
Bristol Myers Squibb	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,563 in reported general payments places this provider in the 85th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Other hematology & oncology in Jacksonville

Edith PerezJacksonville$1.1M
Vamsidhar VelchetiJacksonville$966K
Arnab BasuJacksonville$440K
Sikander AilawadhiJacksonville$179K
James ForanJacksonville$164K
Asher Chanan KhanJacksonville$109K
Martin DietrichRockledge$6.2M
Mark SocinskiOrlando$2.4M
Tarek MekhailOrlando$2.2M
Edgardo SantosFort Lauderdale$2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →